Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Cell or Sell: That Is the Question

September 23rd 2011

In vitro cell manipulation has unleashed the therapeutic potential of human cells.

Dr. Tripathy Discusses Breast Carcinoma Heterogeneity

September 20th 2011

Dr. Debu Tripathy from Norris Comprehensive Cancer Center Discusses Breast Carcinoma Heterogeneity

Dr. Li Describes the Future of Lung Cancer Therapy

September 19th 2011

Dr. Tianhong Li from University of California Davis Cancer Center Describes the Future of Lung Cancer Therapy

Dr. Rugo on VEGF-A as an Avastin Response Predictor

September 16th 2011

Dr. Hope Rugo from UCSF Cancer Center on VEGF-A as an Avastin Response Predictor

Dr. Scagliotti Discusses EGFR Mutations in NSCLC

September 16th 2011

Dr. Giorgio Scagliotti from University of Turin Discusses EGFR Mutations in non-small cell lung cancer

Dr. Dixon on Letrozole With Pathway Inhibitors

September 15th 2011

Dr. J. Michael Dixon from University of Edinburgh on Letrozole Used in Combination With Pathway Inhibitors

Dr. O'Shaughnessy on the Future of TNBC Treatment

September 15th 2011

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Triple Negative Breast Cancer Treatment

Dr. Ellis on Hopeful ER+/HER2- Breast Cancer Paradigms

September 14th 2011

Dr. Matthew Ellis from Washington University on Anticipated ER-positive/HER2-negative Breast Cancer Paradigms

Dr. Scagliotti on Tailored Treatment & Host Genomics

September 13th 2011

Dr. Giorgio Scagliotti from the University of Turin on Tailored Treatment and the Cancer Genome

Dr. McDonald on the Next Step for Angiogenesis Inhibitors

September 13th 2011

Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Next Step for Angiogenesis Inhibitors

Dr. Tripathy Discusses Biomarker Use in Clinical Trials

September 12th 2011

Dr. Debu Tripathy from the USC Norris Comprehensive Cancer Center Discusses Biomarker Use in Clinical Trials

Dr. Li Discusses the EML4-ALK Fusion Gene

September 9th 2011

Dr. Tianhong Li from UC Davis Cancer Center Discusses the EML4-ALK Fusion Gene

Dr. O'Shaughnessy on the Future of Breast Cancer

September 9th 2011

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Breast Cancer Treatment

Dr. McDonald on Resistance to Angiogenesis Inhibitors

September 8th 2011

Dr. Donald M. McDonald from the UCSF Cancer Center Discusses Resistance to Angiogenesis Inhibitors

Dr. Scagliotti Discusses the Future of Lung Cancer Therapy

September 8th 2011

Dr. Giorgio V. Scagliotti from the University of Turin Discusses the Future of Lung Cancer Therapy

Dr. Rugo on Anti-Angiogenesis Therapy Response Predictors

September 7th 2011

Dr. Hope S. Rugo from University of California, San Francisco on Anti-Angiogenesis Therapy Response Predictors

Dr. Ellis on Measuring Endocrine Therapy Efficacy

September 6th 2011

Dr. Matthew J. Ellis from Washington University on Measuring Endocrine Therapy Efficacy With Ki67

4 Questions for Johan Lennartsson, PhD

September 6th 2011

Johan Lennartsson's research focuses on platelet-derived growth factor receptor (PDGFR) and mitogen-activated protein kinase (MAPK) signaling in normal physiology and cancer.

The SCF/KIT Pathway's Roles: Interest in Therapeutic Targets Is Growing

September 2nd 2011

The breadth of the stem cell factor (SCF)/ KIT signaling pathway oncogenic functions and potential role as a therapeutic target are just now becoming clear.

Dr. Tripathy on Connecting Markers to Clinical Outcomes

September 1st 2011

Dr. Debu Tripathy from the USC Norris Cancer Center on Connecting Markers to Clinical Outcomes